Polar Capital Holdings’s Soleno Therapeutics SLNO Stock Holding History

Polar Capital Holdings’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,698,855	Closed	-$56.9M	–	268
2026 Q1	$56.9M	Buy	1,698,855 +561,926	+49%	+$22M	0.2%	89
2025 Q4	$52.6M	Sell	1,136,929 -54,194	-5%	-$2.97M	0.2%	94
2025 Q3	$80.5M	Buy	1,191,123 +373,623	+46%	+$27.7M	0.39%	73
2025 Q2	$68.5M	Buy	817,500 +317,500	+64%	+$23.8M	0.36%	72
2025 Q1	$35.7M	Buy	+500,000	New	+$24.3M	0.22%	114

Polar Capital Holdings's SLNO Position: Q2 2026 in Review

Polar Capital Holdings sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 1,698,855 shares — an estimated $56.9M sold.

Polar Capital Holdings first reported a position in SLNO in Q1 2025 and held it in 5 quarters. The position peaked at $80.5M in Q3 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

Polar Capital Holdings reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
Polar Capital Holdings sold 1,698,855 Soleno Therapeutics shares in Q2 2026, an estimated $56.9M.
Polar Capital Holdings first reported a position in Soleno Therapeutics in Q1 2025 and held it in 5 quarters.
Polar Capital Holdings's Soleno Therapeutics position peaked at $80.5M in Q3 2025.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Polar Capital Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.